Beijing Hope Pharmaceutical Co., Ltd. is a high-tech pharmaceutical company based in China and facing the world. The main business is R&D, production and sales of APIs and APIs, import and export trade, R&D of new pharmaceutical preparations and new drug registration. We have an R&D center in Beijing, a pharmaceutical intermediate production base in Hebei and Zhejiang, and a GMP-certified API production base in Shandong.
*The following content is generated by AI and is for reference only.
Sorafenib tosylate is the p-toluenesulfonate salt form of Sorafenib, a potent oral multi-kinase inhibitor widely recognized in oncology research and clinical practice. With the CAS number 284461-73-0, this compound serves as a critical tool for investigating signal transduction pathways involved in tumor growth and angiogenesis. Its molecular formula is C21H16ClF3N4O·C7H8O3S, reflecting its complex chemical structure designed to target specific serine/threonine kinases.
The primary mechanism of action involves the dual inhibition of Raf kinases (including B-Raf and C-Raf) and receptor tyrosine kinases such as VEGFR-2, VEGFR-3, PDGFR-beta, and KIT. By blocking these pathways, Sorafenib tosylate effectively suppresses tumor cell proliferation while simultaneously inhibiting angiogenesis, thereby starving the tumor of essential nutrients and oxygen. This dual mode of action has made it a standard treatment for advanced renal cell carcinoma (RCC), unresectable hepatocellular carcinoma (HCC), and differentiated thyroid cancer that does not respond to radioactive iodine therapy.
In pharmaceutical research, the tosylate salt form offers improved solubility and stability compared to the free base, facilitating accurate dosing and formulation development. It is extensively utilized in preclinical studies to evaluate drug efficacy, pharmacokinetics, and resistance mechanisms across various cancer models. Researchers rely on high-purity Sorafenib tosylate to validate new therapeutic strategies and combination therapies aimed at overcoming drug resistance. As a cornerstone agent in targeted cancer therapy, it continues to play a pivotal role in advancing personalized medicine and improving survival rates for patients with aggressive malignancies. The compound remains a vital subject of ongoing investigation to expand its application into other solid tumors and hematologic cancers.